ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1213

Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis

Roy Fleischmann1, Jingyu Liu2, Julie Zhu2, Oscar Segurado3 and Daniel Furst*4, 1Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, 2Mallinckrodt Pharmaceuticals, Bedminster, NJ, 3SSI Strategy, San Jose, CA, 4Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA

Meeting: ACR Convergence 2020

Keywords: Biomarkers, clinical trial, Disease Activity, Randomized Trial, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Session Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Assessment of disease activity in RA with validated measures, such as the Disease Activity Score with 28 joint count and erythrocyte sedimentation rate (DAS28-ESR) and the Clinical Disease Activity Index (CDAI), is useful in evaluating therapeutic efficacy and guiding treatment. The multi-biomarker disease activity (MBDA) score was developed to provide an objective laboratory assessment of disease activity. We assessed DAS28-ESR, CDAI, and MBDA scores in a multicenter, placebo-controlled, randomized, phase 4 withdrawal study of repository corticotropin injection (RCI, Mallinckrodt Pharmaceuticals), a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides, in patients with persistently active RA despite treatment with stable low-dose glucocorticoids and 1 or 2 nonbiologic and/or biologic disease-modifying antirheumatic drugs (ClinicalTrials.gov ID: NCT02919761).

Methods: Patients received 80 U of RCI subcutaneously (SC) twice weekly during a 12-week open-label period; those who achieved low disease activity (LDA; DAS28-ESR < 3.2) were randomly assigned to receive 80 U of RCI or placebo SC twice weekly during a 12-week double-blind period. Disease activity was assessed using the DAS28-ESR, CDAI, and MBDA at baseline (BL), week (W) 12, and W24; changes were evaluated via t tests. Correlations for the total MBDA score and its individual components with both DAS28-ESR and CDAI scores at BL, W12, and W24 were assessed via Pearson correlation coefficients for subgroups with/without LDA at W12 or W24. Analyses used the modified intent-to-treat population, defined as patients who received ≥1 dose of study drug and contributed any efficacy data.

Results: RCI therapy was associated with clinically meaningful improvements in disease activity; mean decreases exceeded the minimal clinically important difference thresholds for the DAS28-ESR and CDAI, but not the minimally important difference for the MBDA (Table 1). Statistically significant correlations between MBDA and DAS28-ESR scores were seen at BL and W12 in patients with and without LDA at W12, but low correlation coefficients suggested weak relationships (Table 2). Low correlation coefficients (most nonsignificant) also suggested weak relationships between MBDA and CDAI scores (Table 2). Among individual MBDA components, some significant correlations were noted with both the DAS28-ESR and CDAI scores at BL, W12, and W24; low correlation coefficients suggested weak relationships (data not shown).

Conclusion: In this study of RCI therapy in patients with persistently active RA, clinical disease activity scores were weakly correlated with MBDA total and individual component scores. Similar results have been seen with 3 other agents with different mechanisms of action.1,2 These findings support the 2019 ACR recommendations against use of MBDA as a preferred measure for disease activity in RA.3

References

  1. Reiss WG, et al. Rheumatol Int. 2016;36(2):295-300.
  2. Fleischmann R, et al. Arthritis Rheumatol. 2016;68(9):2083-9.
  3. England BR, et al. Arthritis Care Res (Hoboken). 2019;71(12):1540-55.


Disclosure: R. Fleischmann, Pfizer, 2, 5; J. Liu, Mallinckrodt Pharmaceuticals, 3; J. Zhu, Mallinckrodt Pharmaceuticals, 3; O. Segurado, Mallinckrodt Pharmaceuticals, 9; D. Furst*, Actelion, 1, 2, Amgen, 1, 2, BMS, 1, Corbus, 1, 2, Galapagos, 1, 2, GSK, 1, NIH, 1, Norvatis, 1, 2, Pfizer, 1, 2, Sanofi, 1, Roche/Genentech, 1, Gilead, 1, Horizon, 1, 2, Kadmon, 1, Talaris, 1, 2, CMC Connect (McCann Health Company), 8, Cytori, 5, AbbVie, 5.

To cite this abstract in AMA style:

Fleischmann R, Liu J, Zhu J, Segurado O, Furst* D. Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/discrepancy-between-the-multi-biomarker-disease-activity-score-and-clinical-disease-activity-scores-in-a-2%e2%80%91part-multicenter-study-of-repository-corticotropin-injection-acthar-gel-for/. Accessed July 3, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discrepancy-between-the-multi-biomarker-disease-activity-score-and-clinical-disease-activity-scores-in-a-2%e2%80%91part-multicenter-study-of-repository-corticotropin-injection-acthar-gel-for/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies